Läs upp

Cookies

Den här webbplatsen använder så kallade cookies. Cookies är små textfiler som lagras i din dator och sparar information om olika val som du gjort på en webbsida – t ex språk, version och statistik – för att du inte ska behöva göra dessa val en gång till. Tekniken är etablerad sedan många år tillbaka och används idag på väldigt många webbplatser på Internet.

Du kan när som helst ändra cookieinställningarna för denna webbplats.

FASS logotyp
Receptbelagd

Peka på symbolerna och beteckningarna till vänster för en förklaring.

Företaget deltar inte i Fass, därför finns endast begränsad information om läkemedlet.

Sök apotek med läkemedlet i lager

Sök lagerstatus

Amias

(Parallellimporterat)
MiljöinformationReceptstatusFörmånsstatus
Paranova Läkemedel AB

Tablett 8 mg

Tabletterna har en ljusare färgnyans, saknar prägling och har brytskåra på båda sidor.

Angiotensin II-receptorantagonist

Visa information om det parallellimporterade läkemedlet
Aktiv substans:
ATC-kod: C09CA06
Läkemedel från Paranova Läkemedel AB omfattas av Läkemedelsförsäkringen.
  • Vad är miljöinformation?

Miljöpåverkan (Läs mer om miljöpåverkan)

Miljöinformationen för kandesartan är framtagen av företaget AstraZeneca för Atacand Plus, Atacand®, Atacand® Plus, Racanda

Miljörisk: Användning av kandesartan har bedömts medföra försumbar risk för miljöpåverkan.
Nedbrytning: Kandesartan är potentiellt persistent.
Bioackumulering: Kandesartan har låg potential att bioackumuleras.


Läs mer

Detaljerad miljöinformation

PEC/PNEC = 0.145 μg/L /100 μg/L = 0.00145

PEC/PNEC < 0.1


Environmental Risk Classification


Predicted Environmental Concentration (PEC)


PEC is based on following data:


PEC (µg/L) = (A*109*(100-R))/(365*P*V*D*100)


PEC (µg/L) = 1.5*10-6*A*(100-R)


A (kg/year) = total solid amount API in Sweden year 2016, data from IMS Health. 

R (%) = removal rate (due to loss by adsorption to sludge particles, by volatilization,

hydrolysis or biodegradation) = 0 if no data is available.

P = number of inhabitants in Sweden = 9 *106

V (L/day) = volume of wastewater per capita and day = 200 (ECHA default) (ref.1)

D = factor for dilution of waste water by surface water flow = 10 (ECHA default) (ref.1)

(Note: The factor 109 converts the quantity used from kg to μg).


A = 967.94. Since candesartan cilexetil is a prodrug, mainly excreted as candesartan, conversion is made to equivalent amount of candesartan by 1341.97*(440.46/610.66) (molecular weights for candesartan and candesartan cilexetil, respectively). 1341.97 kg is based on sales figures from IMS for 2016 for candesartan cilexetil.


R = 0


PEC = 1.5 * 10-6 * 967.94 * (100-0) = 0.145 μg/L


Metabolism and excretion

Candesartan cilexetil is a prodrug. After ingestion it is completely converted to the active drug candesartan, which then constitutes approximately 87% of the excreted metabolites. Approximately 33% of the given dose is excreted via the urine and approximately 65% is excreted in the faeces. No prodrug is excreted after use of candesartan cilexetil (ref. 2).


Ecotoxicity data


Candesartan

Endpoint

Species

Common

Name

Method

Time

Result

Reference

NOEC - Based on

Growth

Pseudokirchneriella

subcapitata (formerly known as Selenastrumcapri- cornutum)

Green Alga

OECD 201

72 h

32 mg/L

Note 1a

3

LOEC- Based on

Growth

56 mg/L

Note 1a

ErC50 - Based on

Growth

>56 mg/L

Note 1a

EC50 - Based on

Immobilisation

Daphnia magna

Giant Water

Flea

OECD 202

48 h

>120 mg/L

Note 1a

4

NOEC - Based on

Immobilisation

120 mg/L

Note 1a

NOEC - Based on

Reproduction, Survival or Length

OECD 211

21 d

10 mg/L

Note 1a

5

NOEC - Based on

Hatch, Survival, Length and Dry Weight

Pimephales promelas

Fathead

Minnow

OECD 210

32 d

1.0 mg/L

Note 1a

6

EC50 - Based on

Activated Sludge Respiration Inhibition

-

-

OECD 209

3 h

>100 mg/L

Note 2

7

NOEC - Based on

Activated Sludge Respiration Inhibition

100 mg/L

Note 2

Although there is no environmental exposure to the prodrug, candesartan cilexetil, results for studies are available and have been included for completeness. The results indicate no toxicity in any tested species at the limit of solubility in the test media.


Candesartan Cilexetil

Endpoint

Species

Common

Name

Method

Time

Result

Reference

EbC50 - Based on Area Under Growth Curve

Pseudokirchneriella subcapitata (formerly

known as

S capricornutum)


Green Alga


OECD 201


72 h


>0.012 mg/L

Note 1b

8


ErC50 - Based on Average Specific Growth Rate

>0.012 mg/L

Note 1b

NOEC - Based on

Area Under the

Growth Curve

0.012 mg/L

Note 1b

NOEC - Based on

Average Specific

Growth Rate

0.012 mg/L

Note 1b

LOEC - Overall



>0.012 mg/L

EC50 - Based on

Immobilisation

Daphnia magna


Giant Water

Flea


OECD 202

Part 1


48 h


>0.016 mg/L

Note 1b

9


NOEC - Based on

Immobilisation

0.016 mg/L

Note 1b

LOEC - Overall

>0.016 mg/L

LC50

Oncorhynchus mykiss


Rainbow

Trout


OECD 203


96 h


>0.0172 mg/L

Note 1b

10


NOEC - Based on

Mortality

0.0172 mg/L

Note 1b

LOEC - Overall

>0.0172 mg/L

Note 1a: Concentrations were confirmed by analysis and results expressed as nominal.

Note 1b: Results are expressed as mean measured concentrations.

Note 2: Results are expressed as nominal concentrations.


PNEC (Predicted No Effect Concentration)


The use of candesartan cilexetil will mainly result in the active drug candesartan entering the environment, and therefore the assessment is based on candesartan.


Long-term tests have been undertaken for species from three tropic levels, based on internationally accepted guidelines. Therefore, the PNEC is based on results from the early life stage toxicity test with fathead minnow (Pimephales promelas) and an assessment factor of 10 is applied, in accordance with ECHA guidance (ref. 1).


PNEC = 1000 μg/L/10 = 100 μg/L


Environmental risk classification (PEC/PNEC ratio)


PEC/PNEC = 0.145 µg/L/100 µg/L= 0.00145

i.e. PEC/PNEC < 0.1


The PEC/PNEC ratio decides the wording of the aquatic environmental risk phrase, and the risk phrase for PEC/PNEC ≤ 0.1 reads as follows:


“Use of candesartan has been considered to result in insignificant environmental risk”


In Swedish: ”Användning av kandesartan har bedömts medföra försumbar risk för miljöpåverkan” under the heading ”Miljörisk”.


Environmental Fate Data


Candesartan

Endpoint

Method

Test Substance

Concentration

Time

Result

Reference

Percentage Aerobic

Biodegradation

OECD 301F

100 mg/L

Note 3

28 d

<5%

11

BOD

<0.05 g O2/g

COD

-

-

1.74 g O2/g

Dissipation Half-life

OECD 308

0.1 mg/L in Overlying

Water with High Organic Matter Sediment

Note 3

-

T1/2 = 222 d

12

0.1 mg/L in Overlying

Water with Low Organic Matter

-

T1/2 = 97 d

There was no significant degradation of candesartan under the test conditions. Degradation half lives for the total system could not be calculated.

Degradation Half-life

OECD 309

(Preliminary

Study)

0.2 mg/L in High

Organic Matter

River Water

Note 3

30 d

T1/2 = 12 d

13

0.2 mg/L in High

Organic Matter Suspended Sediment Note 3

T1/2 = 12 d

0.2 mg/L in Low

Organic Matter

River Water

Note 3

T1/2 = 7 d

0.2 mg/L in Low

Organic Matter Suspended Sediment Note 3

T1/2 = 8 d

Percentage

Mineralisation

OECD 309

(Preliminary

Study)

0.2 mg/L in High or

Low Organic Matter

Suspended Sediment

& Overlying Water

Note 3

30 d

<1 %

13

Percentage

Hydrolysis

OECD 111

10 mg/L

Note 3

5 d

12 % @ pH 5, 50oC

<10 % @ pH 7 & 9, 50oC

14

Hydrolysis Half-life

OECD 111

10 mg/L

Note 3

 

T1/2 ≥1 yr @ 25oC

14

Distribution

Coefficient Octanol

Water

OECD 107

50 & 100 mg/L

-

Log D = 2.11 @ pH 5, 20oC

Log D = - 0.68 @ pH 7, 20oC

15

Partition Coefficient

Octanol Water

Shake flask, OECD107


-

-

log Dow = 2.11 at pH 5

log Dow = -0.675 at pH 7 log Dow = -0.902 at pH 9

17

Note 3: Results are expressed as nominal concentrations.


Candesartan Cilexetil

Endpoint

Method

Test Substance

Concentration

Time

Result

Reference

Percentage

Biodegradation

OECD 301B

15 mg/L Organic

Carbon

Note 3

28 d

<9 % ThCO2

16

Note 3: Results are expressed as nominal concentrations.


Biodegradation

The degradation of candesartan in aquatic sediment systems (Ref 12) was assessed according to the OECD 308 Test Guideline. Only partial dissipation of the radioactivity from the water phase was observed at Day 99, 86% and 57% of the radioactivity remained in the aqueous phase and in the high (HOC) and low (LOC) organic carbon test systems, respectively. The dissipation half lives in the supernatants were calculated as 222 days and 95 days for the high and low organic matter vessels, respectively (simple first order (SFO) half lives). No significant mineralization or formation of volatile organic transformation products was observed and, at the end of the test, 22 and 45% the radioactivity was associated with the sediment phase and in the HOC and LOC, respectively.


The solvent used for the primary sediment extraction was ethanol. Non-extracted radioactivity remaining with the sediment was investigated using extraction solvents differing in polarity (methanol, hexane, acetone, 50:50 methanol:dichloromethane, acetonitrile and acidified methanol).


At the end of the study, 87-90% of the radioactivity associated with water phase, and 76-81% of the radioactivity extracted from the sediment phase, was identified as candesartan using thin layer liquid chromatography. Two minor degradation products were observed but neither represented >10% of the applied radioactivity.

candesartan is not readily biodegradable.


Based on the data above the phrase ‘Candesartan is potentially persistent” is chosen.


In Swedish: “Kandesartan är potentiellt persistent” under the heading “Nedbrytning”.


Bioaccumulation

Since Log P < 4 the phrase ‘Candesartan has low potential for bioaccumulation’ is assigned.


In Swedish: ”Kandesartan har låg potential att bioackumuleras” under the heading “Bioackumulering”.


Physical Chemistry Data


Physical Chemistry Data - Candesartan

Endpoint

Method

Test Conditions

Result

Reference

Solubility Water

Note 4

-

<100 mg/L

18

Dissociation

Constant

UV Adsorption

Note 4

-

pKa = 3.8

(Carboxylic acid and tetrazole ring)

18

-

pKa = 2.1

(Benzimidazole ring)

Adsorption

Coefficient

OPPTS 835.1110

0.26 mg/L in

Sewage Sludge

Kd = 17

19

Note 4: This study pre‑dates current ERA regulatory requirements and may not have been undertaken to standardised test guidelines.


Physical Chemistry Data - Candesartan Cilexetil

Endpoint

Method

Test Conditions

Result

Reference

Solubility Water

High

Performance Liquid Chromatography Note 5

25ºC

<0.05 mg/L

20

Dissociation

Constant

UV Adsorption

Note 5

pH 6.9, 20ºC

pKa(1) = 2.1

(Benzimidazole

Ring)

20

pKa(2) = 4.6 (Tetrazole Ring)

Note 5: This study pre-dates current ERA regulatory requirements and may not have been undertaken to standardised test guidelines.


References

  1. ECHA, European Chemicals Agency, 2008 Guidance on information requirements and chemical safety assessment. 


  2. Excretion balance and absolute bioavailability study with 14C-labelled candesartan cilexetil after a single oral and intravenous dose in healthy male volunteers. Report No. SH-ACH-0001. Astra Hässle AB (1996).


  3. Candesartan: Toxicity to the green alga Pseudokirchnerilla subcapitata. Smyth D.V. AstraZeneca Brixham Environmental Laboratory 2007. Report BL8486.


  4. Candesartan: Acute Toxicity to Daphnia Magna. Bowles A.J. AstraZeneca Brixham Environmental Laboratory 2004. Report BL7774.


  5. Candesartan: Chronic Toxicity to Daphnia Magna. Caunter J.E. Brixham AstraZeneca Environmental Laboratory 2008. Report BL8516.


  6. Candesartan: Determination of effects on the early-life stage of the fathead minnow (Pimephales promelas). Caunter J.E. AstraZeneca Brixham Environmental Laboratory 2007. Report BL8494.


  7. Candesartan: Effect on the Respiration Rate of Activated Sludge. Daniel M. AstraZeneca Brixham Environmental Laboratory 2007. Report BL8471.


  8. Inhibition of Growth to the Alga Selenastrum capricornutum. S.D. Mattock. Covance Laboratories Ltd 1997. Report BD3824.


  9. Acute Toxicity to Daphnia magna. S.D. Mattock. Covance Laboratories Ltd 1997. Report BD3825.


  10. Acute Toxicity to Oncorhynchus mykiss. S.D. Mattock. Covance Laboratories Ltd 1997. Report BD3826.


  11. Determination of 28 day ready biodegradability. Bowles A.J.; Daniel M. AstraZeneca Brixham Environmental Laboratory 2004. Report BL7773.


  12. Candesartan: Aerobic transformation in aquatic sediment systems. MacLean S.A. AstraZeneca Brixham Environmental Laboratory 2008. Report BL8479.


  13. Candesartan: Aerobic transformation in aquatic systems screen. Noble H. AstraZeneca Brixham Environmental Laboratory 2009. Report BR0051.


  14. Candesartan: Hydrolysis as a function of pH - Preliminary study. Trollope H. AstraZeneca Brixham Environmental Laboratory 2007. Report BL8449.


  15. CANDESARTAN: Determination of n-octanol/water distribution coefficient. Trollope H. AstraZeneca Brixham Environmental Laboratory 2007. Report BL8450.


  16. Assessment of ready biodegradability of carbon dioxide evolution; Candesartan cilexitil. Mattock S.D. Covance Report 1997. Report BD3974.


  17. Candesartan: Determination of n-octanol/water distribution coefficient. Report No. BL 8450/B. AstraZeneca Brixham Environmental Laboratory, Brihxam, UK. November 2007.


  18. Physical and Chemical Characteristics of CV-11974 (Candesartan). Takeda Chemical Industries Ltd. Report BD4180.


  19. Candesartan: Adsorption and desorption to sewage sludge. MacClean S.A. AstraZeneca Brixham Environmental Laboratory 2007. Report BL8467.


  20. Marketing S1.03 General Properties for Candesartan Cilexitil (TCV-116). Naoki Kaida; Takeda Chemical Industries Ltd 2010. Report BD4181.